Products

Resolor® (prucalopride)

Our lead product, Resolor® (prucalopride), is developed for the treatment of severe chronic constipation in patients who are not adequately relieved by laxative treatments. Resolor has recently received EU marketing approval for the symptomatic treatment of Chronic Constipation (CC) in women in whom laxatives fail to provide adequate relief.

Resolor is also under review by the Swiss authorities, Swissmedic. Resolor is the first in an innovative class of highly selective and enterokinetic compounds.

Product pipeline

In addition to Resolor (prucalopride), we have advanced our other clinical and pre-clinical development programmes that now include two drug candidates in Phase II. M0002 is in Phase II development for ascites, while M0003 is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patients refractory to PPIs, and paediatric reflux. A third drug candidate, M0004, which is a backup to M0003, is in Phase I.

We have also two prioritised compounds out of our preclinical portfolio, M0014 and M0012 and two extensive compound libraries, which reinforce this portfolio.

More information is available in our research section.